What drove BAYN.DE stock higher today?

BAYN.DE stock rose after pipeline news and pre-conference positioning ahead of the J.P. Morgan Healthcare event, combined with active trading on U.S. litigation developments.

Is BAYN.DE stock cheap on valuation?

Valuation is mixed: price-to-sales **0.81** and price-to-book **1.26** look reasonable, but negative trailing EPS **-0.20** and high leverage push some analysts to apply a discount.

What is Meyka AI’s view on BAYN.DE stock?

Meyka AI rates BAYN.DE **70.84/100** (Grade B+, Suggestion: BUY), balancing strong cash flow metrics against legal and leverage risks; this is informational, not investment advice.

Which catalysts should investors watch for BAYN.DE stock?

Key catalysts are J.P. Morgan conference updates, Phase II/III trial readouts, and major litigation rulings in the U.S., all of which can drive volatility and re-rate the stock.

DE Stocks

Bayer AG (BAYN.DE) closed €38.32 on 06 Jan 2026: heavy 4.00M volume, watch pipeline

ByDanny Kontos January 6, 2026January 6, 2026

Bayer AG (BAYN.DE) closed €38.32 on XETRA in Germany on 06 Jan 2026, making it one of the day’s most active names with 4,000,960 shares traded. BAYN.DE stock jumped 0.37 or 0.97% intraday as investors digested pipeline news and legal headlines. We open with price, volume and context because those three metrics drove today’s most active status and set the near-term trading tone.